INTRODUCTION
The interaction of trans-acting factors and their respective cisacting elements are crucial in the determination of gene expression. TPA (12-O-tetradecanoyl-phorbol-13-acetate)-responsive element (TRE) is a well characterized as-acting element composed of a 7 bp palindromic sequence. This sequence was originally identified in the enhancer region of the SV40, human metallothionein n A and phorbol ester responsive genes (1 -3) and is the specific binding site of activator protein-1 (API). API is a heterodimer composed of the products of the jun and fos oncogenes, which dimerize through a leucine zipper domain (4) . Individually, Jun and Fos do not bind to the TRE, although Jun, but not Fos, can form homodimers that can bind the TRE with low affinity and activate gene transcription (4) (5) (6) .
The palindromic sequence of TRE is essential for the high affinity binding of API. Changing the consensus sequence by as little as a single base changes the binding profile of this element. The cAMP-responsive element (CRE) has a single base addition between positions 4 and 5 with respect to the TRE, yet binds API with only a low affinity. CRE is the high affinity binding site for the homodimer binding cAMP-responsive element binding protein (CREB). Interestingly, while API can bind CRE, CREB cannot bind TRE, suggesting intrinsic differences between the API and CREB protein complexes (7) .
The cellular and molecular mechanisms involved in the specific expression of marker genes during tumorigenesis are not well understood. In the course of investigating changes in the pattern of rat liver protein expression during carcinogenesis, we observed a very high increase in the expression of glutathione transferase P (GST-P) (8) . GST-P, an enzyme that catalyzes the conjugation of glutathione to electrophilic compounds, is virtually undetectable in normal liver but is highly expressed in chemically induced hepatocarcinogenesis (8) (9) (10) (11) and is positively correlated with multi-drug resistance (12, and references therein). The subsequent isolation and cloning of the GST-P gene has allowed the identification of its regulatory regions (13) , a silencer element with multiple m-elements (14) and a powerful enhancer region 2500 bp upstream (15) . This enhancer was further divided into two regions, GPEI and II. GPEI is a powerful enhancer and is the dominant element controlling GST-P expression, while GPEH is a weak enhancer. The core sequence of GPEI consists of a palindromic dyad of TRE-like sequence motifs (16) . The downstream element, with the exception of a single C-T substitution at position 4, is homologous with the consensus TRE sequence. The upstream element, separated from the downstream element by 3 bp, has substitutions at positions -9 (G -C) and -11 (C-G) with respect to an inverse oriented TRE, designated here ERT (see Materials and Methods). However GPEI, unlike TRE, mediates very high transcription enhancing activity in API-lacking cells, with the orientation and spacing of the TRE half-sites essential for activity (17) .
To investigate the role API may play in GPEI-mediated activation, and to identify non-API factors that may be involved in activation, the enhancing and binding activities of GPEI and TRE were compared under a variety of conditions in F9 and HeLa cells. We find that API can contribute to GPEI-mediated transcription activation, but does not sufficiently account for all of GPETs enhancing capability. Rather, another transcription factor requiring the entire core sequence of GPEI for binding (API binds only the downstream element) contributes to GPEImediated activation. We suggest that this naturally occurring variation on the TRE-sequence motif encodes the binding site for a novel fra/u-acting factor that is likely to play a central role in GST-P gene expression during hepatocarcinogenesis.
MATERIALS AND METHODS
Cell culture and transfection assays HeLa and F9 embryonal carcinoma cells were maintained at 37°C in a 5% CO 2 environment in minimal essential media supplemented with 10% fetal bovine serum (FBS). For transient expression assays, cells were transfected with 1 or 4 /xg of reporter DNA plus effector DNA, with the total plasmid amount adjusted to 16 /ig with Bluescript plasmid DNA. HeLa cells were glycerol shocked 4h after initial addition of DNA (18) . Following growth for 48h, cells were lysed and total cellular protein determined. DNA transfection into F9 cells was performed as described by Chen and Okayama (19) . Chloramphenicol acetyl aransferase (CAT) activities were determined using 25 fig of total cellular protein as described (20) . Transfections were performed a minimum of two times with at least two different preparations of reporter plasmid.
Nuclear extract preparation, gel retardation assay Nuclear extracts were prepared as described by Fujita, et al. (21) or Dignam et al. (22) 
The underlined sequence represents the consensus element(s) of each sequence. Base differences between GPEI and TRE are shown by double underlined in the upper strand of GPEI.
Plasmid constructions GPEI/A-56 CAT contains the 122 bp GPEI containing GST-P enhancer attached to the CAT structural gene under control of the GST-P promoter (16) . Collagenase (-517/-42) TK CAT (Col-TRE/TK CAT) construction has been described (1). For expression vectors, mouse c-jun (Nhel-ScaThyu/i-B (Smal-EcoRI) and jun-D (EcoRI-EcoRI) fragments were cloned into HindlllHpal site of a pRSV CAT expression plasmid after removal of the CAT gene. AfosB (Sall-BamHI) (a generous gift from Y. Nakabeppu) was cloned into a /3-actin expression vector (pH/SApr-1). Mouse antisenseyaj and jun expression vectors are under control of the SV40 promoter and were generous gifts of P.Herrlich (23, 24) .
RESULTS

Jun family and GPEI enhancement of activation
Sequence homology between TRE and the core element of GPEI suggests that GPEI is an API-dependent enhancer. GPEI, however, has been shown to be active in F9 embryonal carcinoma cells, whereas TRE-enhanced transcription is inactive (17) . As F9 cells are considered to be lacking API, we considered a mechanism of activation involving Jun-B or Jun-D. DNA binding domains of these Jun proteins are homologous to those in c-Jun (25) (26) (27) , and both have been suggested to have transcription enhancing activity at TRE sequences (28, 29) . Fig. 1 shows that GPEI mediates strong transcriptional enhancing activity in F9 cells and is not significantly stimulated by the co-transfection of c-jun. This is in striking contrast to the TRE-enhancer containing construct, which has virtually no activity in the absence of API, but is dramatically stimulated by c-jun co-transfection. When jun B and jun D were tested in the co-transfection assays, we again observe very little effect on GPEI-mediated transcription enhancement. However, in this case, both of these Jun proteins are also basically without effect on TRE-mediated transcription although Jun D, but not Jun B, could offer a small degree of transactivation. It is unlikely that these data are derived from minor population of differentiated F9 cells which transfect much more efficiently than their undifferentiated counterparts, since we always use fresh frozen stock cells for each assay and check the cells by microscope, and there is no significant variation of transfection efficiency. In transfection experiments utilizing C127 cells, which are reportedly low in all three Jun proteins (26), GPEI-enhanced construct behaved analogously as in F9 cells, having high activity and showing little influence from any of the co-transfected ./"H/J constructs. The TRE-enhanced construct also behaved analogously (data not shown).
The high level of GPEI-mediated transcription in cells low in API-activity, as well as the inability of co-transfected c-jun to stimulate activity, suggests GPEI is not an API responsive enhancer. However, we could not rule out the possibility that undetectable levels of API, either alone or with another factor, can mediate GPEI-dependent transcriptional activation. To address this possibility, co-transfection experiments were performed utilizing expression vectors encoding antisense yw/i and fos. In HeLa cells, both antisense constructs virtually completely attenuate Col-TRE/TK CAT activity, confirming the API-dependent nature of this activity (Fig. 2, lanes 4-6) . Antisense jun also significantly decreases the activity of GPEI/A-56 CAT. In this case, although relative activity in the presence of antisense jun is similar in both constructs, GPEI/A-56 CAT retains significantly more activity; antisense fos also decreases GPEI/A-56 CAT activity, but with a much lower efficacy (Fig. 2, lanes 1 -3) . In F9 cells, neither antisense jun nor antisense fos co-transfection decreases GPEI/A-56 CAT activity (Fig. 2, lanes 7-9) . Col-TRE/TK CAT, without the additional co-transfection of c-jun, is inactive in F9 cells. In case of co-transfection of c-jun expression vector with Col-TRE/TK CAT, stimulating effect of c-jun observed in Fig. 1 was attenuated, indicating that antisense constructs were functional in F9 cells (data not shown).
Antisense DNA experiments suggest that endogenous API participates in the activation of GPEI in HeLa cells. On the other hand, the lack of effect of antisense DNA in F9 cells suggests a Jun/API -independent mechanism of activation. In the absence of the upstream half-site, the downstream element confers API-responsiveness to GPEI (17 heterodimer formation. In F9 cells, the stimulation of Col-TRE/TK CAT that is normally seen with the co-transfection of c-jun is partially prevented by the additional co-transfection of AfosB (Fig. 3A, lanes 5-7) . GPEI/A-56 CAT is active without c-jun co-transfection and, in contrast to being inhibited by AfosB, is stimulated to a small extent; inhibition occurs when c-jun is co-transfected with AfosB (Fig. 3A, lanes 1 -4) . In HeLa cells, both GPEI/A-56 CAT and Col-TRE/TK CAT are active without the additional co-transfection of c-jun . In these cells, AfosB cotransfection variably inhibits Col-TRE/TK CAT activity, with inhibition ranging from 0 to 40% (Fig. 3B, lanes 5-6) . In agreement with our observations in F9 cells, AfosB causes a small stimulation of GPEI/A-56 CAT when transfected alone, and a decrease in activity when co-transfected with c-jun (Fig. 3B,  lanes 1-4) . AfosB also partially inhibits the increase in Col-TRE/TK CAT activity that occurs with the additional cotransfection of c-jun in HeLa cells (Fig. 3B, lanes 7-9) . The reason why AfosB only causes a significant inhibition of Col-TRE/TK CAT activity in HeLa cells when co-transfected with c-jun may be related to high-affinity heterodimer formation of c-Jun and c-Fos. AfosB is likely an inefficient competitor of cFos once a c-Jun/c-Fos heterodimer has formed.
Detection of GPEI binding factors
Although API contributes to GPEI-mediated transcription activation in HeLa cells, GPEI/A-56 CAT activation appears to be independent of API in F9 cells. To identify protein factors that interact with GPEI, footprinting analysis was performed using API-lacking F9 cell nuclear extract and the 122 bp GST-P enhancer containing the GPEI core sequence. Numerous areas including GPEI core element were protected by this analysis (data not shown). To clearly resolve nucleoproteins that bind specifically to GPEI versus those that require only TRE for binding, comparative binding analysis was performed using nuclear extracts from both F9 and HeLa cells and oligonucleotides of the core sequences of GPEI, TRE and ERT. When GPEI oligonucleotide is used as the binding substrate, three major nucleotide complexes are resolved from HeLa cell nuclear extract which show a differential and distinct pattern of competition (Fig. 4A, lanes 1-6) . The middle nucleoprotein complex (# 1) is competed by both TRE and GPEI. The upper nucleoprotein complex (# 2), which resolves as a doublet but shows very weak binding activity, is competed only by GPEI while the lower nucleoprotein complex (# 3) is competed by both GPEI and ERT. AP2 and SPl-site oligonucleotides offer no competition for the formation of any of these complexes. When F9 nuclear extract is used (Fig. 4A, lanes 7-12) , nucleoprotein complexes #2 and #3 are again resolved and demonstrate the same competition pattern as with HeLa cell nuclear extract. Very weak signal of complex # 1 is detected in F9 nuclear extract. This binding is probably due to a c-fos complex with low amounts of c-jun, or jun-D which is expressed at relatively high levels but is thought to be non-functional (26) . Other complexes resolved with both nuclear extracts and labeled GPEI oligonucleotide were nonspecific, as judged by the lack of a consistent pattern of appearance nor a specific competition profile.
The multiple nucleoprotein complexes observed with GPEI can be localized to specific portions of the oligonucleotide by utilizing the half-site sequences of TRE and ERT as substrates. A TRE oligonucleotide, representing the downstream halfsite of GPEI, forms a single nucleoprotein complex with HeLa nuclear extract migrating at position # 1 (Fig. 4B) . Binding is competed by both TRE and GPEI, but not by ERT nor any of the non-specific competitors. The ERT oligonucleotide, in contrast, forms a single nucleoprotein complex that migrates at position #3 (Fig. 4C) . Binding is competed by GPEI and by ERT, but not TRE nor any of the other oligonucleotides. This data suggests that nucleoprotein #1 is API, nucleoprotein #2 is a binding factor requiring the entire GPEI sequence, and nucleoprotein # 3 is a factor requiring only the upstream half-site for binding. Note that when using HeLa nuclear extract, endogenously present API does bind to GPEI. This, in connection with the antisence DNA data, supports involvement of API in GPEI mediated activation in API-containing cells. In F9 cells, other factors bind to GPEI. However, the possibility of requirement of API for complex # 2 formation cannot be excluded, although pre-incubation of neither TRE nor ERT competitor can compete for binding.
DISCUSSION
GPEI, although composed of two TRE-like sequences, can mediate transcription activation in the absence of API (17) . The downstream TRE half-site of GPEI confers API binding and responsiveness. The upstream, inverse oriented TRE-like sequence (ERT) binds a non-API factor that may contribute to mz/is-activation, but has no activity on its own. Together, the two halfsites activate through the binding of multiple factors that may act cooperatively. Evidence for the role of a novel factor in GPEI-mediated activation versus that of API can be summarized as follows. In support of API involvement is: 1) GPEI and TRE share sequence homology; 2) GPEI/A-56 CAT activity is higher in API-containing cells than in API-lacking cells; 3) GPEI/A-56 CAT can be stimulated by c-jun co-transfection (albeit slightly); 4) Antisenseju/i and fos can attenuate GPEI/A-56 CAT activity in HeLa cells; 5) Both GPEI and TRE oligonucleotides generate a nucleoprotein complex from HeLa cell nuclear extract with identical electrophoretic mobilities that is competed by unlabeled TRE oligonucleotide.
In support of the involvement of a novel factor is: 1) Transcription activation by GPEI requires an inverse oriented upstream TRE half-site in addition to the API-responsive downstream half-site (17); 2) GPEI mediates transcription activation in both HeLa and F9 cells; 3) The influence of cotransfected c-jun on GPEI/A-56 CAT activity is minimal and may be secondary to activation by another factor; 4) In HeLa cells, antisenseyw/z and yew are more effective at attenuating TREmediated transcription than GPEI-mediated transcription. Furthermore, antisense DNA has no effect on GPEI-mediated transcription in F9 cells; 5) AFosB is an ineffective competitor of GPEI/A-56 CAT activity when co-transfected alone, but inhibits activity when co-transfected with c-jun; 6) Both HeLa and F9 cell nuclear extracts generate nucleoprotein complexes with electrophoretic mobilities distinct from those generated with TRE alone and are not competed by TRE oligonucleotides.
GPEI exhibits a dyad symetry that is a common motif of many DNA-binding proteins, where each half-site serves as a contact point for a transacting factor that acts as a dimer (31) . Often, as is the case with Lex A (32, 33) and the gluticorticoid receptor binding (34) , the proteins bind as homodimers. GPEI half-sites, in contrast, bind different proteins, with GPEI as a whole apparently binding as many as three protein (complexes). These nucleoproteins can be distinguished by their distinct electrophoretic mobilities and their differential ability to be competed by oligonucleotides of GPEI, TRE and ERT (see figure  4) . The downstream halfsite (TRE) binds API and, in the absence of the upstream halfsite (ERT), is activated by c-Jun/APl. Although GPEI can clearly also be influenced by endogenous API, GPEI mediates a greater degree of fra/is-activation than a single TRE does [or even a direct repeat of TRE's (17)], suggesting API does not fully account for all fra/u-activation. However, this downstream element remains essential even in the absence of API, as the lack of any transcriptional activity without it (17) and the ability of Jun/A-FosB to attenuate activity demonstrate. ERT, in turn, binds a separate factor with high affinity.
Evidence that API does not bind ERT include: 1) ERT has no transcriptional activity on its own in API-containing or -lacking cells and c-jun co-transfection can not fra/u-activate through ERT (17); 2) ERT binding protein (EBP) has a differential migration profile than API; and 3) TRE doe not compete for binding at ERT. Together, both half-sites are required for API-independent transcriptional activation, and also demonstrate a third pattern of binding. The slow mobility of this GPEI binding factor (termed GBP), combined with the palindromic dyad motif of GPEI and the ability to maintain activity even when both half-sites are separated by as much as 13 bps (17), suggests that this factor is likely composed of multible subunits.
Many trans-acting factors require palindromic sequences for binding and activation, and several other ds-activating elements have also been shown to bind multiple factors. These fra/w-acting factors utilize a single DNA element, or minor variations thereof, to bind heterologous proteins. GPEI, on the other hand, uses two palindromically oriented elements. An analogous example of this is the hormone response element (HRE), which consists of two 8 bp half-sites. The relative orientation and spacing of these halfsites dictates differential binding specificity to thyroid hormone, retinoic acid, estrogen and vitamin D 3 (35, 36) . Like GPEI, a very high affinity binding site (to thyroid hormone) is created when these half-sites are separated by 3 bp and orientated as inverted palindromes.
We previously performed the dimethylsulfate methylation interference assay using nuclear extract of rat hepatoma cell line dRLh84 and significant interference signal was observed in only downstream TRE (16) . In this paper, we have shown that other factors bind GPEI. GBP utilizes the entire GPEI binding sequence while API and EBP utilize individual half-sites. It is unlikely, however, that these proteins together form GBP, as neither halfsite alone could attenuate GBP binding activity. Furthermore, the binding activity of GBP appeared similar in both F9 and HeLa cells, and GPEI-mediated transcription is high in both cell types, even though F9 cells are deficient in API. Thus when API is activating at GPEI, it is doing so independently of GBP.
Although endogenous API influences GPEI, several lines of evidence suggest that a unique GPEI activating factor, which may incorporate EBP, is the principal mechanism responsible for transactivation. In cultured cells, endogenous API can activate, but co-transfected c-jun/c-fos (API) has minimal effect. In animals, both GST-P and c-jun are increased during the early stages of chemical hepatocarcinogenesis whereas in normal liver, when c-jun mRNA is also present, GST-P is not expressed. We could establish no correlation between c-jun and GST-P expression in normal liver, primary cultured hepatocytes or various hepatoma cell lines (S. Morimura, unpublished data). Although in the in vivo situation GBP and EBP take on primary roles in the activation of the GST-P gene, changes of levels expressed during hepatocarcinogenesis are stilll unclear. Further purification of GBP and EBP, characterization of complex #2, and determination of their levels in hyperplastic nodule and hepatocellular carcinoma will clarify the functional aspects of these protein factors in GST-P gene expression.
